---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-083457"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2023-07-24T23:59:59+00:00"
generated_at: "2026-06-13T03:57:17.841192+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics wins Federal Circuit appeal in Liquidia patent litigation; Yutrepia approval delayed

## Summary
- Federal Circuit affirmed Liquidia's Yutrepia infringes United Therapeutics' '793 patent; FDA approval blocked until patent expires May 14, 2027.
- Court confirmed Liquidia would induce infringement by marketing Yutrepia; all '793 claims held valid over invalidity challenges.
- Federal Circuit also affirmed certain claims of U.S. Patent No. 9,593,066 are either invalid or not infringed by Liquidia.
- Both parties may request rehearing; PTAB IPR decision finding '793 unpatentable is on appeal by United Therapeutics.
- District court order barring FDA final approval remains unless infringed claims are found invalid after exhaustion of appeals.

## SEC filing metadata
- accession: 0001104659-23-083457
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2023-07-24T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000110465923083457/0001104659-23-083457-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000110465923083457/tm2321916d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-083457
- JSON: https://secwatch.observer/filing/0001104659-23-083457.json
- Plain text: https://secwatch.observer/filing/0001104659-23-083457.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.